不同剂型重组人生长激素对特发性矮小症的疗效分析

目的 分析不同剂型重组人生长激素治疗特发性矮小症的疗效差异及与疗效相关的治疗前相关影响因素。方法 回顾性分析2020年1月—2021年12月于四川省妇幼保健院儿童保健科诊断为特发性矮小，年龄在4~8岁且使用不同剂型重组人生长激素进行治疗的儿童，比较不同组别儿童不同治疗时期身高增长值、生长因子水平变化等，同时对影响身高增长效果的治疗前相关因素进行Logistic回归分析。结果 接受不同剂型重组人生长激素治疗儿童，2组间除治疗第3个月IGF-BP₃增值具有统计学差异(P<0.05)外，其余治疗各阶段身高、IGF-1及IGF-BP₃增长值在2组间均无明显差异；初始使用年龄对儿童身高增长结局有影响，且差异有统计学意义(OR=0.258，95%CI 0.109~0.609，P=0.002)，其余因素无明显影响。结论 不同剂型重组人生长激素对特发性矮小儿童的治疗疗效无明显差异；初始使用年龄是影响生长激素使用效果的主要因素之一。

Effect Analysis of Different Formulation of Recombinant Human Growth Hormone on Idiopathic Short Stature

OBJECTIVE To analyze the different therapeutic effects of different formulations of recombinant human growth hormone on idiopathic short stature and the related factors before treatment. METHODS Retrospective analysis was performed on children aged 4-8 years who were diagnosed as idiopathic short stature at the Child Health Department of Sichuan Maternal and Child Health Care Hospital from January 2020 to December 2021 and treated with different formulation of recombinant human growth hormone. The changes of height growth value and growth factor levels of children in different groups during different treatment periods were compared. At the same time, Logistic regression analysis was carried out on the related factors affecting the effect of height growth before treatment. RESULTS There was no significant difference in height, IGF-1 and IGF-BP₃ growth between the two groups at each stage of treatment, except for the statistical difference in IGF-BP₃ increment at the third month of treatment(P<0.05); The age of treatment had an effect on the height growth outcome of children, and there was statistical significance(OR=0.258, 95%CI 0.109-0.609, P=0.002). The remaining factors had no obvious influence. CONCLUSION There is no difference in the therapeutic effect of different formulation of recombinant human growth hormone on idiopathic short stature. The age of beginning use is the main factor that affects the effect of using growth hormone.